HOME >> BIOLOGY >> NEWS
Joslin-led study uncovers role of appetite hormone MCH in insulin production

BOSTON Jan. 25, 2007 -- A new Joslin Diabetes Center-led study has shown conclusively that a neuropeptide, melanin concentrating hormone (MCH), found in the brain and known for its role in increasing appetite in people, plays a role in the growth of insulin-producing beta cells and the secretion of insulin. This finding has the potential to spur the development of new treatments for diabetes that stimulate the production of insulin-producing beta cells in the pancreas. This latest research, conducted with researchers at Beth Israel Deaconess Medical Center in Boston and other institutions, will appear in the February 2007 issue of Diabetes.

An earlier Joslin-led study examined the connection between obesity and MCH, which plays a critical role in energy balance and appetite, observing an increase in the number of beta cells when MCH levels are high. This was a new finding that had not been observed before. Although MCHs role in appetite control is well known, its effects on the secretion of endocrine hormones has not been fully understood.

Its a very logical connection, says Rohit N. Kulkarni, M.D., Ph.D., investigator at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School, who led the study. Whenever you eat food, your body needs more insulin. When MCH induces appetite, it simultaneously increases insulin secretion from beta cells and enhances growth of beta cells. If the proteins that mediate the growth mechanism can be identified, it could lead to the development of new drugs that would enhance beta cell growth to treat type 1 and type 2 diabetes.

In type 1 diabetes (insulin-dependent) diabetes, which accounts for 5 to 10 percent (between 700,000 and 1.4 million people) of diabetes cases in the United States, an autoimmune process has destroyed the insulin-producing islet cells in the pancreas. In type 2 diabetes, the far more common form of the disease, the body doesnt produce enough insulin an
'"/>

Contact: Marjorie Dwyer
marjorie.dwyer@joslin.harvard.edu
617-732-2415
Joslin Diabetes Center
26-Jan-2007


Page: 1 2

Related biology news :

1. Joslin-led study reveals new findings on insulin signaling in the liver
2. Joslin-led study reveals findings on how insulin-producing beta cells grow and function
3. Big hips, big belly? Its in your genes, Joslin-led study shows
4. New study warns limited carbon market puts 20 percent of tropical forest at risk
5. Clones on task serve greater good, evolutionary study shows
6. Pollution causes 40 percent of deaths worldwide, study finds
7. A study by the MUHC and McGill University opens a new door to understanding cancer
8. New study suggests Concord grape juice may provide protection against breast cancer
9. Preclinical study links gene to brain aneurysm formation
10. In limiting life span, study finds booming bacteria innocent
11. Multicenter study nets new lung tumor-suppressor gene

Post Your Comments:
(Date:3/11/2015)... , March 11, 2015   The ... its platform to scientifically measure and harness music ... to real-time biometrics and objective measurements of physiology, ... music at scale in large populations. It is ... technologists and clinicians perform rigorous studies and accelerate ...
(Date:3/10/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ... biometric authentication company focused on the growing mobile ... has been named the "Number One Best Tech ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a web ... and lifestyle that have a unique function or design.  ...
(Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
(Date:3/30/2015)... , March 30, 2015 CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... Drug Administration (CFDA) has approved the Company,s application to ... clear cell carcinoma (OCCC) patients for its proprietary drug ...
(Date:3/30/2015)... GERMANTOWN, Md. , March 30, 2015  /PRNewswire/ ... a leader in synthetic biology, and Merck Serono, ... Germany , today announced an exclusive ... commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. ... to develop innovative therapies that modulate the immune ...
(Date:3/30/2015)... Washington, USA (PRWEB) March 29, 2015 ... and the United States and plenary talks by four ... SPIE Optics + Optoelectronics next month in ... technical presentations in 17 conferences alongside a two-day exhibition. ... and photonics , the event will run 13-16 April ...
(Date:3/30/2015)... 2015  Naldemedine, an investigational peripherally acting mu-opioid ... Co., Ltd., met its primary and secondary endpoints ... the treatment of opioid-induced constipation (OIC) in adult ... Study results showed that naldemedine (0.2 mg tablet ... of spontaneous bowel movement (SBM) compared with placebo ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: